Replies to post #106407 on Biotech Values

[DewDiligence]

IDIX—was just stating I had a hard time thinking the increase in IDIX was due to AASLD meeting.

You may be right about AASLD, and it’s possible that Roche’s machinations vis-à-vis Danoprevir have had more of an impact than I stated (although I would’ve thought relatively few investors understood Roche’s motivation for ending the ITMN collaboration).

I'll keep my 2 cents to myself. :)

Please don’t do that—this message board is intended to be a venue for opinions :- )